Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000046

Drug Information
NameAmsacrine
SynonymsNSC249992; CI 880; Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-; Lamasine; Amekrin; UNII-00DPD30SOY; D02321; Amsacrine [USAN:BAN:INN]; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; AB1004823; AC1L1D3L; Methanesulfonanilide, 4'-(9-acridinylamino)-3'-methoxy-; Amsacrine (USAN/INN); BRN 0500176; NCIMech_000607; Methanesulfonamide, N-(4-(9-acridinylamino)-3-methoxyphenyl)-; SN 21429; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; NSC-141549; NSC-156303; C01553; m-AMSA; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; mAMSA; nchembio.100-comp16; Neuro_000118; NSC 249992; SN-11841; meta-AMSA; amsacrine; Lopac-A-9809; AMSA, M-; Amsine; Amsidine; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; NSC-249992; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; SN11841; LS-1319; CI-880; meta-Amsacrine; nAMSA; DB00276; C21H19N3O3S; Methanesulfon-m-anisidide, 4'-(9-acridinylamino)-; CID2179; AMSA P-D; EINECS 257-094-3; Amsidyl; Amsacrinum [INN-Latin]; Lopac0_000154; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; CHEBI:2687; NCGC00162077-01; CCRIS 1027; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; WLN: T C666 BNJ IMR BO1 DMSW1; 5-22-11-00030 (Beilstein Handbook Reference); N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; CHEMBL43; NCI60_001995; NSC 156303; NCGC00015113-03; Amsacrina [INN-Spanish]; Amecrin; Acridinyl Anisidide; nchem.981-comp12; NCI-249992; 4'-(9-Acridinylamino)methanesulphon-m-anisidide; Amsidyl (TN); HSDB 7087; NCGC00015113-01; Acridinylanisidide; 51264-14-3; Amsacrinum; Amsacrina; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; I14-9555; Cain's Acridine
Trade NameAcridinyl anisidide; m-AMSA
CompanyTravenol Laboratories, Inc
IndicationAcute lymphoblastic leukemia
[ICD9: 204.0   ICD10: C91.0]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-
7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)
InChIKeyXCPGHVQEEXUHNC-UHFFFAOYSA-N
Canonical SMILESCOC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 51264-14-3
FormulaC21H19N3O3S
PubChem Compound IDCID 2179.
PubChem Substance IDSID 4711.
ChEBI2687;
SuperDrug ATC IDL01XX01
SuperDrug CAS ID051264143;
TargetDNA topoisomerase IIInhibitor[2]
Ref 1Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) utricle. J Assoc Res Otolaryngol. 2009 Jun;10(2):191-203. Epub 2009 Feb 25. To Reference
Ref 2Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543